Jonathan Wolleben
Stock Analyst at JMP Securities
(3.85)
# 718
Out of 4,761 analysts
185
Total ratings
45.05%
Success rate
11.12%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTGX Protagonist Therapeutics | Reiterates: Market Outperform | $58 | $38.75 | +49.68% | 10 | Feb 7, 2025 | |
| PHVS Pharvaris | Maintains: Market Outperform | $46 → $55 | $16.49 | +233.54% | 10 | Jan 31, 2025 | |
| KALV KalVista Pharmaceuticals | Initiates: Market Outperform | $19 | $10.03 | +89.43% | 1 | Jan 31, 2025 | |
| BCRX BioCryst Pharmaceuticals | Reiterates: Market Outperform | $18 | $9.21 | +95.44% | 5 | Jan 31, 2025 | |
| ATXS Astria Therapeutics | Initiates: Market Outperform | $26 | $6.81 | +281.79% | 1 | Jan 31, 2025 | |
| MDGL Madrigal Pharmaceuticals | Reiterates: Market Outperform | $427 | $336.23 | +27.00% | 11 | Jan 10, 2025 | |
| DBVT DBV Technologies | Reiterates: Market Outperform | $10 | $4.40 | +127.53% | 12 | Jan 10, 2025 | |
| RYTM Rhythm Pharmaceuticals | Reiterates: Market Outperform | $75 | $56.07 | +33.76% | 2 | Dec 23, 2024 | |
| SVRA Savara | Reiterates: Market Outperform | $9 | $2.69 | +234.57% | 8 | Dec 19, 2024 | |
| HGV Hilton Grand Vacations | Maintains: Market Outperform | $55 → $50 | $41.01 | +21.92% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $91 | $23.77 | +282.92% | 7 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $90 | $76.79 | +17.20% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $87 | $37.46 | +132.25% | 13 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $146.07 | - | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $2.56 | +212.50% | 7 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $3 | $0.42 | +614.29% | 7 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Accumulate | $420 → $485 | $607.38 | -20.15% | 1 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $3 | $0.29 | +950.05% | 6 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $19 → $23 | $7.51 | +206.26% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $15 | $2.98 | +403.36% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $48 → $32 | $4.12 | +676.70% | 8 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $66 → $68 | $52.45 | +29.65% | 8 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $25 | $3.19 | +683.70% | 11 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $25 → $24 | $6.43 | +273.25% | 10 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $24 → $22 | $7.00 | +214.29% | 16 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $0.75 | +961.01% | 11 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $0.95 | +426.32% | 9 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $24 | $35.26 | -31.93% | 1 | May 12, 2023 |
Protagonist Therapeutics
Feb 7, 2025
Reiterates: Market Outperform
Price Target: $58
Current: $38.75
Upside: +49.68%
Pharvaris
Jan 31, 2025
Maintains: Market Outperform
Price Target: $46 → $55
Current: $16.49
Upside: +233.54%
KalVista Pharmaceuticals
Jan 31, 2025
Initiates: Market Outperform
Price Target: $19
Current: $10.03
Upside: +89.43%
BioCryst Pharmaceuticals
Jan 31, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $9.21
Upside: +95.44%
Astria Therapeutics
Jan 31, 2025
Initiates: Market Outperform
Price Target: $26
Current: $6.81
Upside: +281.79%
Madrigal Pharmaceuticals
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $427
Current: $336.23
Upside: +27.00%
DBV Technologies
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $10
Current: $4.40
Upside: +127.53%
Rhythm Pharmaceuticals
Dec 23, 2024
Reiterates: Market Outperform
Price Target: $75
Current: $56.07
Upside: +33.76%
Savara
Dec 19, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $2.69
Upside: +234.57%
Hilton Grand Vacations
Dec 18, 2024
Maintains: Market Outperform
Price Target: $55 → $50
Current: $41.01
Upside: +21.92%
Dec 18, 2024
Reiterates: Market Outperform
Price Target: $91
Current: $23.77
Upside: +282.92%
Dec 16, 2024
Reiterates: Market Outperform
Price Target: $90
Current: $76.79
Upside: +17.20%
Dec 16, 2024
Reiterates: Market Outperform
Price Target: $87
Current: $37.46
Upside: +132.25%
Dec 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $146.07
Upside: -
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $2.56
Upside: +212.50%
Dec 11, 2024
Downgrades: Market Perform
Price Target: $3
Current: $0.42
Upside: +614.29%
Nov 13, 2024
Downgrades: Accumulate
Price Target: $420 → $485
Current: $607.38
Upside: -20.15%
Sep 26, 2024
Reiterates: Market Outperform
Price Target: $3
Current: $0.29
Upside: +950.05%
Sep 13, 2024
Maintains: Market Outperform
Price Target: $19 → $23
Current: $7.51
Upside: +206.26%
Sep 10, 2024
Initiates: Market Outperform
Price Target: $15
Current: $2.98
Upside: +403.36%
Aug 15, 2024
Maintains: Market Outperform
Price Target: $48 → $32
Current: $4.12
Upside: +676.70%
Jun 18, 2024
Maintains: Market Outperform
Price Target: $66 → $68
Current: $52.45
Upside: +29.65%
May 31, 2024
Reiterates: Market Outperform
Price Target: $25
Current: $3.19
Upside: +683.70%
May 10, 2024
Maintains: Market Outperform
Price Target: $25 → $24
Current: $6.43
Upside: +273.25%
May 8, 2024
Maintains: Market Outperform
Price Target: $24 → $22
Current: $7.00
Upside: +214.29%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $0.75
Upside: +961.01%
Mar 13, 2024
Reiterates: Market Outperform
Price Target: $5
Current: $0.95
Upside: +426.32%
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $35.26
Upside: -31.93%